Enterprise Value
-318.7K
Cash
2.798M
Avg Qtr Burn
-2.434M
Short % of Float
9.81%
Insider Ownership
7.36%
Institutional Own.
22.71%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Oral Fadraciclib (CDK2 & CDK9) Details Solid tumor/s, Lymphoma, Cancer | Phase 2 Data readout | |
Oral Plogosertib Details Lymphoma, Solid tumor/s | Phase 1 Data readout |